VenoVision aims to help stabilize patients and reduce deterioration by providing low-cost, objective, noninvasive hemodynamic monitoring across the continuum of care, including inpatient, outpatient, care facility, home, and telemedicine settings.
The companys remote patient monitoring solution is designed to help medical teams improve the therapeutic management and outcomes of obese and overweight cardiovascular patients who are either suffering or at risk of heart failure and hemodynamic complications.
VenoVisions deep-thermal imaging device and monitoring platform provide easy-to-use, contactless remote monitoring. Designed to overcome the challenges of obese and overweight neck pathology, the platform uses multiparametric hemodynamic vital signs from signals processing algorithms to deliver data comparable to Swan-Ganz or ultrasound.
The company is focused on driving down the billions of dollars currently spent on preventable deterioration and rehospitalization. VenoVision has completed a proof-of-concept clinical trial, designed a prototype, and patented its technology.